Baricitinib for the treatment of refractory vascular Beh çet's disease

CONCLUSIONS: Our study suggests that baricitinib is well-tolerated and effective in treating refractory vascular/cardiac BD patients.PMID:36967024 | DOI:10.1016/j.clim.2023.109298

Source: Clinical Immunology - March 26, 2023 Category: Allergy & Immunology Authors: Zhimian Wang Xiaoou Wang Weiwei Liu Yuhua Wang Jinjing Liu Li Zhang Shangzhu Zhang Xinping Tian Yan Zhao Wenjie Zheng Source Type: research